Literature Title

First Author

Type

Publication Year

Publication Journal

Brief Summary

Clinical Practice Pearl

Reference #

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

Wilding

Original Research

2022

Diabetes, Obesity, and Metabolism Journal of Pharmacology and Therapeutics

Cessation of semaglutide as a therapeutic intervention resulted in a return to baseline weight comparable to the weight before starting on semaglutide

Overweight and obesity appear to be a chronic disease that may require ongoing pharmacological intervention to halt its progression and abate its related comorbidities.

18

Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide

Sherwin

Observational Prospective Study || Original Research

2023

NIH PMC Pub Med Central

Use of gastric ultrasound to assess fat content in gastric tissue after eight hours since semaglutide dose; there was slowing of gastric emptying in the semaglutide group and higher risk for aspiration if under general anesthesia.

Semaglutid prolongs satiety in patients by slowing gastric emptying; treatment withdrawal may be beneficial prior to undergoing surgery with general anesthesia.

19